PROCEPT Advances Prostate Cancer Program with Water IV Milestones

What happened

PROCEPT BioRobotics has completed enrollment in its WATER IV randomized trial comparing Aquablation therapy to radical prostatectomy and received FDA IDE approval for a second protocol evaluating Aquablation versus active surveillance. These milestones expand the clinical evidence base for Aquablation therapy beyond benign prostatic hyperplasia into prostate cancer treatment. While positive for the long-term adoption narrative, this development does not alter the near-term financial trajectory, as the company continues to invest heavily in R&D, widening adjusted EBITDA losses to $(18.1)M in Q1'26. The stock remains a WAIT, as operating leverage has not yet materialized despite strong procedure growth and improved pricing discipline. Until future quarters show sequential loss narrowing and sustained consumables conversion above 95%, the clinical progress alone is insufficient to support a higher valuation.

Implication

Successful WATER IV results could expand the total addressable market and strengthen guideline inclusion, but the path to profitability requires several quarters of execution on commercial reset and cost control. Investors should wait for evidence of declining EBITDA losses before adding positions.

Thesis delta

No material change to the investment thesis. The clinical milestones support the long-term adoption story but do not address the immediate need for operating leverage and cash burn reduction. The WAIT rating and entry point of $23 remain appropriate until Q2 or Q3 data show sequential improvement in adjusted EBITDA and handpiece conversion holds near 95%.